Figure 3. Effect of idarucizumab (1 mg/mL) on thrombin generation parameters, determined by a calibrated automated thrombogram (CAT) assay, and lysis time, determined by a turbidimetric assay, of dabigatran samples at C-Trough (upper panels, n=8) and C-Peak (lower panels, n=8).

Differences between samples with (grey boxes) and wihout (empty boxes) idarucizumab were assessed by Wilcoxon’s test (*: p=0.008; †: p=0.023). Idarucizumab had no effect on CAT velocity index (not shown in figure). Please note that, due to the limited volumes of plasma, C-Peak and C-Trough samples were obtained from different patients.